Valneva SE Logo

Valneva SE

VLA.PA

(0.2)
Stock Price

2,18 EUR

-7.33% ROA

-20.21% ROE

-11.29x PER

Market Cap.

427.434.459,00 EUR

110.12% DER

0% Yield

-21.49% NPM

Valneva SE Stock Analysis

Valneva SE Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Valneva SE Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock maintains a fair debt to equity ratio (78%), indicating a reasonable balance between the money it owes and the ownership it possesses.

2 ROE

Negative ROE (-3.5%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (-1.33%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.43x) suggests it's overvalued, potentially making it an expensive investment.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-2.836), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Valneva SE Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Valneva SE Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Valneva SE Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Valneva SE Revenue
Year Revenue Growth
2005 3.011.000
2006 2.329.000 -29.28%
2007 866.000 -168.94%
2008 3.418.000 74.66%
2009 3.096.000 -10.4%
2010 8.395.000 63.12%
2011 10.263.000 18.2%
2012 3.431.000 -199.13%
2013 30.445.000 88.73%
2014 36.923.000 17.54%
2015 78.359.000 52.88%
2016 94.062.000 16.69%
2017 105.291.000 10.66%
2018 113.035.000 6.85%
2019 126.196.000 10.43%
2020 110.321.000 -14.39%
2021 348.085.000 68.31%
2022 361.303.000 3.66%
2023 152.284.000 -137.26%
2023 153.713.000 0.93%
2024 152.240.000 -0.97%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Valneva SE Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 9.870.000 100%
2010 13.126.000 24.81%
2011 12.165.000 -7.9%
2012 12.885.000 5.59%
2013 21.423.000 39.85%
2014 22.242.000 3.68%
2015 25.367.000 12.32%
2016 24.589.000 -3.16%
2017 23.356.000 -5.28%
2018 12.193.000 -91.55%
2019 37.883.000 67.81%
2020 84.454.000 55.14%
2021 173.283.000 51.26%
2022 104.922.000 -65.15%
2023 64.968.000 -61.5%
2023 56.894.000 -14.19%
2024 66.208.000 14.07%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Valneva SE General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 3.063.000 100%
2010 3.686.000 16.9%
2011 262.000 -1306.87%
2012 4.177.000 93.73%
2013 14.720.000 71.62%
2014 14.142.000 -4.09%
2015 14.394.000 1.75%
2016 14.412.000 0.12%
2017 15.545.000 7.29%
2018 36.302.000 57.18%
2019 27.513.000 -31.94%
2020 38.006.000 27.61%
2021 47.606.000 20.17%
2022 34.073.000 -39.72%
2023 48.668.000 29.99%
2023 47.799.000 -1.82%
2024 44.708.000 -6.91%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Valneva SE EBITDA
Year EBITDA Growth
2005 930.000
2006 537.000 -73.18%
2007 -3.018.000 117.79%
2008 -1.822.000 -65.64%
2009 -3.950.000 53.87%
2010 -5.796.000 31.85%
2011 -1.030.000 -462.72%
2012 -7.572.000 86.4%
2013 -12.828.000 40.97%
2014 -11.217.000 -14.36%
2015 -1.240.000 -804.6%
2016 -908.000 -36.56%
2017 7.353.000 112.35%
2018 14.396.000 48.92%
2019 10.110.000 -42.39%
2020 -45.324.000 122.31%
2021 -46.865.000 3.29%
2022 -113.174.000 58.59%
2023 -88.268.000 -28.22%
2023 -86.498.000 -2.05%
2024 -87.176.000 0.78%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Valneva SE Gross Profit
Year Gross Profit Growth
2005 2.536.000
2006 1.603.000 -58.2%
2007 -817.000 296.21%
2008 673.000 221.4%
2009 -2.161.000 131.14%
2010 1.856.000 216.43%
2011 3.541.000 47.59%
2012 -7.664.000 146.2%
2013 13.937.000 154.99%
2014 19.779.000 29.54%
2015 31.398.000 37.01%
2016 50.986.000 38.42%
2017 59.312.000 14.04%
2018 69.604.000 14.79%
2019 76.228.000 8.69%
2020 56.019.000 -36.08%
2021 160.165.000 65.02%
2022 36.862.000 -334.5%
2023 68.396.000 46.11%
2023 48.538.000 -40.91%
2024 58.368.000 16.84%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Valneva SE Net Profit
Year Net Profit Growth
2005 -1.220.000
2006 -243.000 -402.06%
2007 -3.362.000 92.77%
2008 -2.389.000 -40.73%
2009 -6.144.000 61.12%
2010 -7.962.000 22.83%
2011 -4.419.000 -80.18%
2012 -14.841.000 70.22%
2013 -24.110.000 38.44%
2014 -26.272.000 8.23%
2015 -20.617.000 -27.43%
2016 -49.184.000 58.08%
2017 -11.482.000 -328.36%
2018 3.264.000 451.78%
2019 -1.744.000 287.16%
2020 -64.393.000 97.29%
2021 -73.425.000 12.3%
2022 -143.279.000 48.75%
2023 -136.900.000 -4.66%
2023 -101.429.000 -34.97%
2024 -99.732.000 -1.7%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Valneva SE Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 -1 0%
2014 0 0%
2015 0 0%
2016 -1 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 -1 0%
2021 -1 0%
2022 -1 100%
2023 0 0%
2023 -1 0%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Valneva SE Free Cashflow
Year Free Cashflow Growth
2005 -3.065.000
2006 -3.881.000 21.03%
2007 -4.698.000 17.39%
2008 -3.154.000 -48.95%
2009 -3.199.000 1.41%
2010 -8.795.000 63.63%
2011 -16.774.000 47.57%
2012 -14.042.000 -19.46%
2013 -24.177.000 41.92%
2014 -18.682.000 -29.41%
2015 -26.980.000 30.76%
2016 2.823.000 1055.72%
2017 8.791.000 67.89%
2018 13.135.000 33.07%
2019 -5.355.000 345.28%
2020 118.267.000 104.53%
2021 -16.270.000 826.9%
2022 -274.665.000 94.08%
2023 -72.618.000 -278.23%
2023 -228.414.000 68.21%
2024 -41.850.000 -445.79%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Valneva SE Operating Cashflow
Year Operating Cashflow Growth
2005 681.000
2006 -2.735.000 124.9%
2007 -3.565.000 23.28%
2008 -1.842.000 -93.54%
2009 939.000 296.17%
2010 -3.154.000 129.77%
2011 -8.656.000 63.56%
2012 -13.220.000 34.52%
2013 -20.903.000 36.76%
2014 -14.944.000 -39.88%
2015 -24.334.000 38.59%
2016 6.505.000 474.08%
2017 12.829.000 49.29%
2018 16.306.000 21.32%
2019 5.529.000 -194.92%
2020 137.738.000 95.99%
2021 76.901.000 -79.11%
2022 -245.343.000 131.34%
2023 -71.401.000 -243.61%
2023 -214.102.000 66.65%
2024 -42.199.000 -407.36%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Valneva SE Capital Expenditure
Year Capital Expenditure Growth
2005 3.746.000
2006 1.146.000 -226.88%
2007 1.133.000 -1.15%
2008 1.312.000 13.64%
2009 4.138.000 68.29%
2010 5.641.000 26.64%
2011 8.118.000 30.51%
2012 822.000 -887.59%
2013 3.274.000 74.89%
2014 3.738.000 12.41%
2015 2.646.000 -41.27%
2016 3.682.000 28.14%
2017 4.038.000 8.82%
2018 3.171.000 -27.34%
2019 10.884.000 70.87%
2020 19.471.000 44.1%
2021 93.171.000 79.1%
2022 29.322.000 -217.75%
2023 1.217.000 -2309.37%
2023 14.312.000 91.5%
2024 -349.000 4200.86%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Valneva SE Equity
Year Equity Growth
2005 4.778.000
2006 4.659.000 -2.55%
2007 29.010.000 83.94%
2008 27.416.000 -5.81%
2009 22.529.000 -21.69%
2010 44.288.000 49.13%
2011 40.445.000 -9.5%
2012 26.194.000 -54.41%
2013 144.111.000 81.82%
2014 124.444.000 -15.8%
2015 144.335.000 13.78%
2016 100.051.000 -44.26%
2017 92.669.000 -7.97%
2018 143.186.000 35.28%
2019 135.153.000 -5.94%
2020 77.422.000 -74.57%
2021 170.581.000 54.61%
2022 219.797.000 22.39%
2023 157.521.000 -39.54%
2023 128.247.000 -22.83%
2024 166.278.000 22.87%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Valneva SE Assets
Year Assets Growth
2005 14.601.000
2006 14.922.000 2.15%
2007 39.584.000 62.3%
2008 41.384.000 4.35%
2009 45.954.000 9.94%
2010 79.499.000 42.2%
2011 73.083.000 -8.78%
2012 53.667.000 -36.18%
2013 254.391.000 78.9%
2014 227.517.000 -11.81%
2015 275.187.000 17.32%
2016 206.883.000 -33.02%
2017 189.343.000 -9.26%
2018 229.907.000 17.64%
2019 264.723.000 13.15%
2020 449.164.000 41.06%
2021 817.352.000 45.05%
2022 621.344.000 -31.55%
2023 520.539.000 -19.37%
2023 469.391.000 -10.9%
2024 466.569.000 -0.6%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Valneva SE Liabilities
Year Liabilities Growth
2005 9.823.000
2006 10.263.000 4.29%
2007 10.574.000 2.94%
2008 13.968.000 24.3%
2009 23.425.000 40.37%
2010 35.211.000 33.47%
2011 32.638.000 -7.88%
2012 27.473.000 -18.8%
2013 110.280.000 75.09%
2014 103.073.000 -6.99%
2015 130.852.000 21.23%
2016 106.832.000 -22.48%
2017 96.674.000 -10.51%
2018 86.721.000 -11.48%
2019 129.570.000 33.07%
2020 371.742.000 65.15%
2021 646.771.000 42.52%
2022 401.547.000 -61.07%
2023 363.018.000 -10.61%
2023 341.144.000 -6.41%
2024 300.290.000 -13.6%

Valneva SE Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.09
Net Income per Share
-0.23
Price to Earning Ratio
-11.29x
Price To Sales Ratio
2.83x
POCF Ratio
-1.69
PFCF Ratio
-1.87
Price to Book Ratio
2.2
EV to Sales
3.35
EV Over EBITDA
-5.58
EV to Operating CashFlow
-2.33
EV to FreeCashFlow
-2.22
Earnings Yield
-0.09
FreeCashFlow Yield
-0.53
Market Cap
0,43 Bil.
Enterprise Value
0,51 Bil.
Graham Number
2.51
Graham NetNet
-0.88

Income Statement Metrics

Net Income per Share
-0.23
Income Quality
6.69
ROE
-0.2
Return On Assets
-0.07
Return On Capital Employed
-0.28
Net Income per EBT
1.25
EBT Per Ebit
0.25
Ebit per Revenue
-0.68
Effective Tax Rate
-0.25

Margins

Sales, General, & Administrative to Revenue
0.32
Research & Developement to Revenue
0.42
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.39
Operating Profit Margin
-0.68
Pretax Profit Margin
-0.17
Net Profit Margin
-0.21

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.56
Free CashFlow per Share
-1.64
Capex to Operating CashFlow
-0.05
Capex to Revenue
0.08
Capex to Depreciation
1.96
Return on Invested Capital
-0.36
Return on Tangible Assets
-0.07
Days Sales Outstanding
73.88
Days Payables Outstanding
33.58
Days of Inventory on Hand
192.48
Receivables Turnover
4.94
Payables Turnover
10.87
Inventory Turnover
1.9
Capex per Share
0.08

Balance Sheet

Cash per Share
0,95
Book Value per Share
1,20
Tangible Book Value per Share
1.02
Shareholders Equity per Share
1.2
Interest Debt per Share
1.51
Debt to Equity
1.1
Debt to Assets
0.39
Net Debt to EBITDA
-0.86
Current Ratio
2.63
Tangible Asset Value
0,14 Bil.
Net Current Asset Value
-0,03 Bil.
Invested Capital
347369000
Working Capital
0,17 Bil.
Intangibles to Total Assets
0.05
Average Receivables
0,03 Bil.
Average Payables
0,02 Bil.
Average Inventory
48726000
Debt to Market Cap
0.43

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Valneva SE Dividends
Year Dividends Growth

Valneva SE Profile

About Valneva SE

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

CEO
Mr. Thomas Lingelbach
Employee
700
Address
6 rue Alain Bombard
Saint-Herblain, 44800

Valneva SE Executives & BODs

Valneva SE Executives & BODs
# Name Age
1 Mr. Franck Grimaud MBA
Chief Business Officer
70
2 Mr. Frederic Jacotot
Vice President of Legal & IP, General Counsel, and Corporate Secretary
70
3 Dr. Hanneke Schuitemaker Ph.D.
Chief Scientific Officer
70
4 Mr. Thomas Lingelbach
President, Chief Executive Officer & Director
70
5 Dr. Juan-Carlos Jaramillo M.D.
Chief Medical Officer
70
6 Mr. Joshua Drumm Ph.D.
Vice President of Investor Relations
70
7 Ms. Laetitia Bachelot-Fontaine
Vice President of Global Communications & European Investor Relations
70
8 Mr. Peter Buhler
Chief Financial Officer
70
9 Ms. Dipal Patel
Chief Commercial Officer
70
10 Mr. Vincent Dequenne
Chief Operating Officer
70

Valneva SE Competitors

Innate Pharma S.A. Logo
Innate Pharma S.A.

IPH.PA

(0.5)
DBV Technologies S.A. Logo
DBV Technologies S.A.

DBV.PA

(2.5)
Genfit S.A. Logo
Genfit S.A.

GNFT.PA

(0.8)
Valneva SE Logo
Valneva SE

VALN

(0.2)
Nanobiotix S.A. Logo
Nanobiotix S.A.

NANO.PA

(1.8)